Skip to main content
SpringerLink
Log in

Some Aspects of the Cost of Schizophrenia in France

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

This study aimed to investigate how patients with schizophrenia were treated and to evaluate the cost of treatment in medical and social terms in France.

The study was questionnaire-based. 6000 French hospital and community psychiatrists in the public and private sectors received the questionnaire. The 494 psychiatrists who responded described the treatment prescribed for, and social assistance provided to, the last patient consulting for schizophrenia — as defined by the criteria of the third edition (revised) of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) — either as an outpatient or as an inpatient in the last year.

The clinical, epidemiological and therapeutic data collected on 356 (72%) patients receiving outpatient treatment and 138 (28%) patients receiving inpatient treatment in the public (242 patients; 49%) or private (252 patients; 51 %) sectors were processed by medical and economic modelling.

The mean (± standard deviation) time from symptom onset to study entry was 11 ± 8 years, while the mean time from first hospital admission to study entry was 9.5 ± 8 years. The mean time from symptom onset to initial hospitalisation was 25 ± 4 months.

224 patients had been hospitalised in a psychiatric ward at least once in the previous year (45%). The average duration of hospitalisation was 82 ± 96 days. During the year of the study, 122 patients received part-time treatment in a day hospital or intermediate facility (e.g. occupational therapy centres, therapeutic workshops and therapeutic apartments), 39 (8%) on a daily basis and 83 (17%) one or more times a week; medical care lasted 130 ± 137 days and 107 ± 89 days, respectively.

The annual complete cost of medical management of the 477 evaluable patients in the study was F27 471 511 (1992 values). The overall annual treatment cost (medical and social) was F1 533 724 for medication (5.6% of the complete cost), F2 600 673 for visits (9.5%), F8 285 900 for intermediate facilities (30.1 %) and F15 051 214 (54.8%) for hospitalisation. The social allowance cost was Fl0 926 000. The average annual costs of medical care and social allowance per patient with schizophrenia were respectively estimated at F54 970 and F22 905. The annual cost of medical management of schizophrenia in France was thus F12.37 billion ($US2.34 billion).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989; 15: 81–9

    Article  PubMed  CAS  Google Scholar 

  2. Tabbane K, Joober R, Spadone C, et al. Mortality and cause of death in schizophrenia: review of literature. Encephale 1993; 19(1): 23–8

    PubMed  CAS  Google Scholar 

  3. Opler LA, Caton CLM, Shrout P, et al. Symptom profiles and homelessness in schizophrenia. J Nerv Ment Dis 1994; 182: 174–8

    Article  PubMed  CAS  Google Scholar 

  4. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949–58

    Article  PubMed  CAS  Google Scholar 

  5. Torrey EF. Prevalence studies in schizophrenia. Br J Psychiatry 1987; 150: 598–608

    Article  PubMed  CAS  Google Scholar 

  6. Book JA, Wetterberg L, Modrzewska K. Schizophrenia in a North Swedish geographical isolate 1900–1977: epidemiology, genetics and bio-chemistry. Clin Genet 1978; 14: 373–94

    Article  PubMed  CAS  Google Scholar 

  7. Jablensky A. Epidemiology of schizophrenia: a European perspective. Schizophr Bull 1986; 12: 52–73

    Article  PubMed  CAS  Google Scholar 

  8. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. Psychol Med 1986; 16: 909–28

    Article  PubMed  CAS  Google Scholar 

  9. Terkelsen KG, Menikoff A. Measuring the cost of schizophrenia: implications for the post institutional era in the United States. Pharmacoeconomics 1995; 8(3): 199–222

    Article  PubMed  CAS  Google Scholar 

  10. Gunderson JG, Mosher LR. The cost of schizophrenia. Am J Psychiatry 1975; 132: 901–6

    PubMed  CAS  Google Scholar 

  11. Andrews G, Hall W, Goldstein G, et al. The economic costs of schizophrenia. Arch Gen Psychiatry 1985; 42: 537–43

    Article  PubMed  CAS  Google Scholar 

  12. Davies LM, Drummond MP. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5

    Article  Google Scholar 

  13. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993; 16(2): 413–23

    PubMed  CAS  Google Scholar 

  14. Meltzer HY, Cola P, Way L, et al. Cost of effectiveness of clozapine in antipsychotic-resistant schizophrenia. Am J Psychiatry 1993; 150(11): 1630–8

    PubMed  CAS  Google Scholar 

  15. Hafner H, and an der Heiden W. Evaluating effectiveness and cost of community care for schizophrenic patients. Schizophr Bull 1991; 17(3): 441–51

    Article  PubMed  CAS  Google Scholar 

  16. Guelfi JD. Diagnostic and statistical manual of mental disorders (DSM-III-R) [in French]. 3rd rev. Paris: Masson, 1989

    Google Scholar 

  17. Terra JL, Alexandre JY. Epidemiologie de la schizophrenie. In: Rouillon F, Terra JL, Lepine JP, editors. Epidemiologie psychiatrique. Paris: IEEP-Gourcheau, 1995: 133–46

    Google Scholar 

  18. Bonnet C. Quelle est la place de la réinsertion dans la prise en charge à long terme des psychoses schizophreniques. In: Vidon G, editor. Strategies thérapeutiques à long terme dans les psychoses schizophreniques. Frison Roche: Federation Française de Psychiatrie 1994: 381–99

    Google Scholar 

  19. Bernadou M, Bouguelmounna A, Garros MB, et al. Rev Méd de l’Assur Mal 1988; 2: 12–4

    Google Scholar 

  20. Masse G. Developpement de la psychiatrie à l’hôpital général dans la perspective d’une meilleure intégration de la santé mentale au système général de la santé. Paris: Ministère des affaires sociales et de la santé (masse report), 1992 Jan

    Google Scholar 

  21. Frank DD. Economic contribution of families caring for persons with severe and persistent mental illness. NIMH contract no. 87M020295501D, Division of Biometry and Applied Science Research, November 1987. Adm-Pol Mental Health 1990; 18(9)

    Google Scholar 

  22. Andrews G, Hall W, Goldstein G, et al. The economic costs of schizophrenia. Arch Gen Psychiatry 1985; 42: 537–43

    Article  PubMed  CAS  Google Scholar 

  23. Eco Santé France database, CREDES, Medical Demographics

  24. Rouillon F. Enquête épidémiologique des troubles psychiatriques en consultation spécialisée. Encephale 1992; 13: 525–35

    Google Scholar 

  25. Loranger AW. Sex differences in age of onset of schizophrenia. Arch Gen Psychiatry 1984; 41: 157–61

    Article  PubMed  CAS  Google Scholar 

  26. Angermeyer MC, Kühn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull 1990; 16: 293–307

    Article  PubMed  CAS  Google Scholar 

  27. Roche T. Différences sexuelles dans la schizophrenie: Mémoire DES de Psychiatrie. Lyon: Université Lyon I, 1990

    Google Scholar 

  28. Ministère de la Santé. Rapport sur les statistiques de l’hospitalisation en milieu psychiatrique. Paris, 1979

  29. Antoine D, Boisguerin B. L’offre de soins en santé mentale: cadrage statistique. Psychiatr Fr 1992; 4: 5–24

    Google Scholar 

  30. Leguay D, Robert D, Lechertier F, et al. Axes de recherche et résultats d’une enquête départementale d’épidémiologie psychiatrique. J Psychiatr Biol Ther 1988; 28: 26–9

    Google Scholar 

  31. Cohen CI. Poverty and the course of schizophrenia: implications for research and policy. Hosp Community Psychiatry 1993; 44(1): 951–8

    PubMed  CAS  Google Scholar 

  32. Kissling W. Compliance, quality assurance and standard for relapse prevention in schizophrenia. Acta Psychiatr Scand 1994; 89 Suppl. 382: 16–24

    Article  Google Scholar 

  33. Davis JM. Overview: maintenance therapy in psychiatry. 1: schizophrenia. Am J Psychiatry 1975; 132: 1237–45

    PubMed  CAS  Google Scholar 

  34. Davis JM, Malaton L, Watanabe MD, et al. Depot antipsychotic drugs. Drugs 1994; 47(5): 741–73

    Article  PubMed  CAS  Google Scholar 

  35. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974; 31: 67–72

    Article  PubMed  Google Scholar 

  36. Kane JM, Borenstein M. Compliance in the long-term treatment of schizophrenia. Psychopharmacol Bull 1985; 21: 23–7

    PubMed  CAS  Google Scholar 

  37. Taylor PJ, Gunn JC. Violence and psychosis II: effect of psychiatric diagnosis on conviction and sentencing of offenders. BMJ 1984; 289: 9–12

    Article  PubMed  CAS  Google Scholar 

  38. Wilcox DE. The relationship of mental illness to homicide. Am J Forensic Psychiatry 1985; 6: 3–15

    Google Scholar 

  39. Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental illness: 1985. San Francisco (CA): University of California, 1990

    Google Scholar 

  40. Saugstad LF, Odegard O. Mortality in psychiatric hospital in Norway. Acta Psychiatr Scand 1979; 59: 431–47

    Article  PubMed  CAS  Google Scholar 

  41. Herman HE, Baldwin JA, Christie D. A record-linkage study of mortality and general hospital discharges in patients diagnosed as schizophrenics. Psychol Med 1983; 13: 581–93

    Article  Google Scholar 

  42. OCDE Dépenses de santé en France en 1992. OCDE sources transitted on personal request

  43. Desce JM. Psychiatrie et recherche: le budget des soins psychiatriques [editorial]. J Assoc Psychiatr 1993; 1: 2

    Google Scholar 

  44. Davies L, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994; 165 Suppl. 25: 18–21

    Google Scholar 

  45. Ciompi L. Coûts et bénéfices en psychiatrie sociale: faut-il économiser ou développer? Rev Med Suisse Romande 1993; 113: 805–13

    PubMed  CAS  Google Scholar 

  46. Häfner H, Van der Heiden W. Effectiveness and cost of community care for schizophrenic patients. Hosp Community Psychiatry 1989; 40(1): 59–63

    PubMed  Google Scholar 

  47. Counting the cost of schizophrenia [editorial]. Marketletter 1992 Dec; 7: 26–7

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatry Department, Hospital Louis Mourier, Colombes, France

    Frédéric Rouillon

  2. Economic and Public Health Department, Timone Medical University, Marseille, France

    Mondher Toumi & Pascal Auquier

  3. Georges-Yves Dansette Institute, Lyon, France

    Georges-Yves Dansette

  4. Lundbeck SA, Paris, France

    Joseph Benyaya

Authors
  1. Frédéric Rouillon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mondher Toumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Georges-Yves Dansette
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph Benyaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pascal Auquier
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rouillon, F., Toumi, M., Dansette, GY. et al. Some Aspects of the Cost of Schizophrenia in France. Pharmacoeconomics 11, 578–594 (1997). https://doi.org/10.2165/00019053-199711060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199711060-00006

Keywords

Search

Navigation